- In July 2024, Vernacare Ltd (H.I.G. Capital, L.L.C.), a supplier of laparoscopic retrieval bags, announced the transfer of USD 4.54 million in surgical tool operations from China to the U.K. This strategic move aims to enhance the company's manufacturing capabilities at its facilities in Newtown, England, and Worksop, Wales. Additionally, this shift is expected to yield significant savings of approximately USD 324.60 million for the corporation
- In June 2024, Shenzhen Mindray Bio-Medical Electronics Co., Ltd, a prominent player in the industry, participated in the European Association for Endoscopic Surgery International Congress, showcasing its innovative minimally invasive surgical solutions. The company introduced a comprehensive range of both disposable and reusable surgical instruments, aimed at meeting diverse surgical needs. Such initiatives are designed to enhance product visibility and expand market reach across various countries
- In November 2023, Applied Medical Resources Corporation received approval from the U.S. FDA for its Inzii Ripstop Redeployable Retrieval System. This innovative product is specifically designed for the safe removal of calculi, organs, and tissue during both laparoscopic and general surgical procedures. The FDA authorization marks a significant milestone for the company, enhancing its portfolio of surgical solutions
- In November 2022, Johnson & Johnson announced its agreement to acquire Abiomed for approximately USD 16.6 billion, aiming to expand its MedTech business and strengthen its position as a leader in cardiovascular innovation. This acquisition will enhance Johnson & Johnson's portfolio of medical technologies and improve its capabilities in delivering advanced cardiovascular care. By integrating Abiomed's expertise, the company seeks to drive growth and innovation in the cardiovascular sector
- In January 2022, Medtronic PLC announced its intention to acquire Affera Inc., a medical technology company, as part of its strategy to enhance its cardiovascular portfolio. This acquisition is aimed at strengthening Medtronic's capabilities in delivering innovative cardiovascular solutions. By integrating Affera's technologies, Medtronic seeks to drive growth and improve patient outcomes in the cardiovascular field
